HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

TAK 779

structure in first source; discontinued
Also Known As:
N,N-dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium chloride; N-((4-(((6,7-dihydro-2-(4-methylphenyl)-5H-benzocyclohepten-8-yl)carbonyl)amino)phenyl)methyl)tetrahydro-N,N-dimethyl-2H-pyran-4-aminium chloride; TAK-779
Networked: 24 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Fujiwara, Hiromi: 3 articles (12/2005 - 07/2002)
2. Imanishi, Takeshi: 3 articles (12/2005 - 07/2002)
3. Ono, Shiro: 2 articles (12/2009 - 02/2003)
4. Yang, Yi-Fu: 2 articles (12/2009 - 02/2003)
5. Matsushima, Kouji: 2 articles (08/2005 - 07/2002)
6. Gao, Ping: 2 articles (02/2003 - 07/2002)
7. Hamaoka, Toshiyuki: 2 articles (02/2003 - 07/2002)
8. Obika, Satoshi: 2 articles (02/2003 - 07/2002)
9. Barroso, Helena: 1 article (01/2012)
10. Borrego, Pedro: 1 article (01/2012)

Related Diseases

1. Atherosclerosis
2. Acquired Immunodeficiency Syndrome (AIDS)
3. Asthma (Bronchial Asthma)
4. Arthritis (Polyarthritis)
5. Infection

Related Drugs and Biologics

1. LDL Receptors (LDL Receptor)
2. Lipoproteins (Lipoprotein)
3. Carbon
4. Chemokine Receptors
5. enfuvirtide (Fuzeon)
6. Chemokine CCL3
7. CCR Receptors
8. CXCR3 Receptors
9. Defensins
10. CCR5 Receptors (CCR5 Receptor)

Related Therapies and Procedures

1. Intravenous Injections
2. Immunotherapy